[C:1]([C:3]1[N:4]=[C:5]([C:29]2[C:34]([F:35])=[CH:33][CH:32]=[CH:31][C:30]=2[F:36])[O:6][C:7]=1[NH:8][C:9]1[CH:14]=[CH:13][C:12]([NH:15][C:16](=[O:28])[CH2:17][CH2:18][N:19]([CH3:27])C(=O)OC(C)(C)C)=[CH:11][CH:10]=1)#[N:2].C(=O)(O)[O-:38].[Na+].[OH-].[Na+]>S(=O)(=O)(O)O>[F:35][C:34]1[CH:33]=[CH:32][CH:31]=[C:30]([F:36])[C:29]=1[C:5]1[O:6][C:7]([NH:8][C:9]2[CH:14]=[CH:13][C:12]([NH:15][C:16](=[O:28])[CH2:17][CH2:18][NH:19][CH3:27])=[CH:11][CH:10]=2)=[C:3]([C:1]([NH2:2])=[O:38])[N:4]=1A solution of tert-butyl 3-(4-(4-cyano-2-(2,6-difluorophenyl)oxazol-5-ylamino)phenylamino)-3-oxopropyl(methyl)carbamate (0.021 g, 0.04 mmol) in concentrated sulfuric acid (1 ml) was stirred at room temperature overnight. The reaction was basified by addition to sat. sodium bicarbonate and then addition of 6M NaOH (to ˜pH12). The aqueous phase was then extracted with EtOAc, the combined organic phases dried over MgSO4 and the solvent removed in vacuo. The residue was purified by preparative HPLC to afford 2-(2,6-difluorophenyl)-5-(4-(3-(methylamino)propanamido)phenylamino)oxazole-4-carboxamide (0.0038 g, 0.009 mmol, 22%). 1H NMR (CD3OD) δ 2.64 (3H, s), 2.73 (2H, t), 3.20 (2H, masked by CD3OD peak), 7.08 (2H, t), 7.29 (2H, d), 7.45 (1H, m), 7.48 (2H, d), 8.45 (1H, br. s). LCMS (2) Rt: 2.28 min; m/z (ES+) 416.